GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

WeLeader Biomedical Co 7713.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

70.60

+0.14%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About WeLeader Biomedical Co

Its shares trade on Taipei Exchange under the ticker 7713.TWO. It has been listed since 2 January 2024. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.11bn and net income of TWD 208.6m. At that date it held total assets of TWD 2.45bn and shareholders' equity of TWD 1.26bn.

WeLeader Biomedical Co Ltd is a TW-based company operating in Health Care Providers & Services industry. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2024-01-02. WeLeader Biomedical Co Ltd is a Taiwan-based company mainly engaged in the agency and trading business of in vitro diagnostic instruments and reagent-related products, as well as the provision of medical testing-related services. The firm is engaged in providing distribution, after-sales and maintenance services of laboratory reagents, consumables, instruments and equipment, construction planning of medical testing laboratory sites, equipment procurement, operational coaching and other ancillary services, as well as human resources construction and training, operational coaching, and digital medical examination platforms. Products are mainly sold domestically.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
2 Jan 2024

Leadership

Pay as last reported

  • Zhongcai SheCorporate Executive, Director
  • Meiqin ChenIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Kaohsiung, Taiwan, operating in the Health Care sector.
  • Offers agency and trading of in vitro diagnostic instruments and reagents.
  • Provides comprehensive services including distribution, after-sales, and medical testing services.

Weaknesses

  • Primarily focused on domestic sales within Taiwan.
  • Limited to agency and trading business without manufacturing.
  • IPO occurred in 2024, indicating a relatively new market presence.

Opportunities

  • Potential for expansion into international markets beyond Taiwan.
  • Growing demand for in vitro diagnostic products and services.
  • Digital medical examination platforms could attract new clients.

Threats

  • Dependence on domestic market may limit growth potential.
  • Competition in the health care services sector could increase.
  • New entrants in the diagnostic instruments and reagent industry may pose challenges.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.